Prognostic factors and clinical hallmarks of low grade serous ovarian carcinoma: a single center study

Ovarian cancer is the most fatal gynecologic malignancy. Low-grade type represents only 2–5% of all ovarian cancer pathological types. Its clinical characteristics, growth pattern, and response to treatment are distinct from high-grade serous ovarian carcinoma. In this study, we retrospectively evaluated the clinical features, prognostic factors, and survival of patients diagnosed with low-grade serous ovarian cancer from a tertiary cancer centre. This is a retrospective study where all patients diagnosed with low-grade serous ovarian cancer (LGSOC) who presented to a tertiary cancer centre from July 2015 to August 2021 were included. Forty-two patients with low-grade ovarian serous carcinoma were enrolled. The mean age of the patients was 50.17 ± 10.91 years, while the mean Body Mass Index (BMI) was 32.96 ± 6.02 kg/m2. Primary optimal debulking was performed in 18 patients, while interval cytoreduction was done in 17 patients. Suboptimal debulking was performed in 5 patients. Neoadjuvant chemotherapy was administered in 19 patients (45.2%). The median overall survival of LGSOC patients was 95.58 (73.37–117.79) months while the median Progression free survival (PFS) was 56.54 (38.15–74.94) months. Primary cytoreductive surgery is still the cornerstone of the management of LGSOC patients. Neoadjuvant chemotherapy could be a predictor of worse progression-free survival in LGSOC patients presented with advanced disease stage.

Ovarian cancer; Low grade serous; Serous ovarian cancer; Cytoreductive surgery; Interval debulking; Neoadjuvant chemotherapy

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68: 394–424.

[2] Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. Journal of Cancer Epidemiology. 2014; 2014: 437971.

[3] Kang JH, Lai YL, Cheng WF, Kim HS, Kuo KT, Chen YL, et al. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan. Scientific Reports. 2020; 10: 20012.

[4] Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. The American Journal of Surgical Pathology. 2004; 28: 496–504.

[5] Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Current Oncology Reports. 2008; 10: 519–523.

[6] Babaier A, Mal H, Alselwi W, Ghatage P. Low-grade serous carcinoma of the ovary: the current status. Diagnostics. 2022; 12: 458.

[7] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[8] Cree IA, White VA, Indave BI, Lokuhetty D. Revising the who classification: female genital tract tumours. Histopathology. 2020; 76: 151–156.

[9] Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. American Society of Clinical Oncology Educational Book. 2013; 33: e195–e199.

[10] Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, et al. Low grade serous ovarian cancer—a rare disease with increasing therapeutic options. Cancer Treatment Reviews. 2023; 112: 102497.

[11] Moujaber T, Balleine RL, Gao B, Madsen I, Harnett PR, DeFazio A. New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocrine-Related Cancer. 2022; 29: R1–R16.

[12] Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, et al. Low-grade serous ovarian carcinoma. Geburtshilfe Und Frauenheilkunde. 2018; 78: 972–976.

[13] Di Lorenzo P, Conteduca V, Scarpi E, Adorni M, Multinu F, Garbi A, et al. Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. Frontiers in Oncology. 2022; 12: 970918.

[14] Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance. Gynecologic Oncology. 2020; 158: 653–658.

[15] Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. Journal of Clinical Oncology. 2015; 33: 2675–2682.

[16] Chen M, Jin Y, Bi Y, Yin J, Wang Y, Pan L. A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology. OncoTargets and Therapy. 2014; 7: 1891–1899.